1[1]Eberhardt RT, Kevak RM, Kang PM, et al. Angiotensin Ⅱ receptor blockade: an innovative approach to cardiovascular pharmacology. J Clin Pharmacol, 1993, 33:1023
2[2]Timmermans PB, Wong PC, Chiu AT, et al. Angiotensin Ⅱ receptors and angiotensin Ⅱ receptor antagonists. Pharmacol Rev, 1993, 45(Jun):205
3[3]Cavras I. Bradykinin-mediated effects of ACE inhibition. Drug,1992, 42:1020
4[4]Husain A. The chymase-angiotensin system in human. J Hypertens, 1993, 11:1155
5[5]Lacourciere Y, Lefebvre J. Modulation of the reninangiotensin-aldosterone system and cough. Can J Cardiol,1995, 11(Suppl F): 33F
6[6]Roberto F, Sergio A, Luca S, et al. 24 h blood pressure control by once-daily administration of irbesartan assessed by ambulatory blood pressure monitoring. J Hypertens, 1997, 15:1511
7[7]Richard A, Richard AR, Lin CS, et al. Dose-related efficacy of irbesartan for hypertension. Hypertension, 1998, 31:1311
8[8]Fletcher AE, Palmer AJ, Bulpitt CJ. Cough with angiotensin converting enzyme inhibitors: how much of a problem? J Hypertens, 1994, 12(Suppl 2):S43
